Home
/
Calidi Biotherapeutics, Inc.
/
Financials
/
Quarterly
Calidi Biotherapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Calidi Biotherapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2022
$45.0K
Nov 14, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.15M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($5.72M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($5.06M)
May 14, 2025
Q3
2025
Sep 30, 2024
($5.05M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($5.77M)
Aug 8, 2025
Q2
2024
Mar 31, 2024
($7.23M)
Aug 13, 2024
Q1
2025
Mar 31, 2024
($7.23M)
May 14, 2025
Q3
2024
Sep 30, 2023
($2.02M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($12.50M)
Aug 13, 2024
Q3
2023
Jun 30, 2023
($12.50M)
Nov 14, 2023
Q2
2024
Mar 31, 2023
($6.46M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($6.46M)
May 14, 2024
Q3
2023
Mar 31, 2023
($6.46M)
Nov 14, 2023
Q3
2023
Sep 30, 2022
($5.36M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
$4.16M
Aug 21, 2023
Q3
2023
Jun 30, 2022
($4.58M)
Nov 14, 2023
Q3
2023
Mar 31, 2022
($7.74M)
Nov 14, 2023
Q1
2023
Mar 31, 2022
$1.46M
May 15, 2023
Q2
2023
Mar 31, 2022
$1.46M
Aug 21, 2023
Q3
2022
Sep 30, 2021
($823.3K)
Nov 14, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.05M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($5.66M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($5.06M)
May 14, 2025
Q3
2025
Sep 30, 2024
($5.23M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($5.77M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($6.75M)
May 14, 2025
Q3
2024
Sep 30, 2023
($7.22M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($6.54M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($5.41M)
May 14, 2024
Q3
2023
Sep 30, 2022
($6.99M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($361.6K)
Aug 21, 2023
Q1
2023
Mar 31, 2022
($528.9K)
May 15, 2023
Q3
2022
Sep 30, 2021
($1.09M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($83.3K)
Aug 10, 2022